Previous studies have shown that CD73 inhibitors, when combined with immune checkpoint blockade (ICIs), effectively inhibit the progression of pancreatic (22), non-small cell lung cancer (NSCLC) (29), and breast cancers (30) in mouse models. Here, NT5E is linked to breast carcinoma.